Insmed, a biopharmaceutical company focused on inhaled therapeutics for serious lung diseases, has appointed Andrew Drechsler to the position of chief financial officer.
Drechsler brings 15 years of financial and operational leadership experience in both public and private life sciences companies. He joins Insmed from VaxInnate, a privately held clinical-stage biotech developing vaccines for infectious diseases, where he served as CFO. Previously, Drechsler was CFO of publicly-traded Valera Pharmaceuticals where he helped raise $35 million through an initial public offering in 2006. He was also part of the team that negotiated the sale of the company to Indevus Pharmaceuticals in 2007 in a transaction valued at $150 million. Drechsler's duties have also included serving as controller for a variety of companies, including Abbott Laboratories' Point of Care Division and Biomatrix.